BANK JULIUS BAER & CO. A.G., GUERNSEY BRANCH | Market Closed - Swiss Exchange 11:20:00 2024-06-20 am EDT | ||
| 96.75 USD | +1.20% |
|
| 1 month | -0.10% | ||
| 3 months | -2.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 96.75 | +1.20% |
| 24-06-19 | 95.6 | -0.16% |
| 24-06-18 | 95.75 | -0.26% |
| 24-06-14 | 96 | +0.05% |
Delayed Quote Swiss Exchange
Last update June 20, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Reverse Convertibles |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Bank Julius Bär |
| FAQRJB | |
| ISIN | CH1311056068 |
| Date issued | 2024-02-22 |
| Strike | 72.78 $ |
| Maturity | 2025-02-24 (249 Days) |
| Parity | 0.07 : 1 |
| Emission price | 100 $ |
| Emission volume | N/A |
| Settlement | both |
| Currency | USD |
Technical Indicators
| Highest since issue | 99.7 $ |
|---|---|
| Lowest since issue | 95.45 $ |
| Spread | 5 $ |
| Spread % | 0.51% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.15
USD
Average target price
82.7
USD
Spread / Average Target
+30.95%
- Stock Market
- Certificates
- FAQRJB Certificat
